Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis

Interferon β -1b reduces the frequency and severity of relapses of relapsing-remitting multiple sclerosis (MS) and slows the progression of disability in secondary progressive MS. It has a number of immunomodulatory effects but the mechanism of its beneficial effect in MS is unclear. In contrast to its beneficial effect in MS, interferon β -1b has recently been reported to enhance other autoimmune diseases in patients with MS, including autoimmune thyroid disease.¹⁻³ We report the development of autoimmune hypothyroidism in two MS patients receiving interferon β -1b therapy.

A 44-year-old woman with relapsing-remitting MS for six months was commenced on interferon ß-1b therapy, eight million units subcutaneously every second day. Thyroid function tests performed immediately before the commencement of interferon ß-1b showed a normal free T4 level of 11 pmol/L (normal range [NR] 9-23) and a normal thyrotropin level of 3.1 mU/L (NR 0.4-5.0). Five months after the commencement of interferon ß-1b, thyroid function tests were performed because of palpitations and revealed an elevated thyrotropin level of 10 mU/L, a highly elevated level of antithyroid microsomal antibodies (titre 6400) and a normal antithyroglobulin antibody level. These results indicated hypothyroidism due to Hashimoto's thyroiditis, although she had no clinical features of hypothyroidism. She was commenced on L-thyroxine 100 µg daily. She has continued on interferon ß-1b therapy, and her thyroid function has remained adequate on replacement therapy.

A 37-year-old woman with relapsing-remitting MS for 13 years was commenced on interferon β -1b therapy, eight million units subcutaneously every second day. Three months later, she noted weight gain but had no other symptoms of hypothyroidism. Thyroid function tests revealed an elevated thyrotropin level of 80 mU/L, a highly elevated level of antithyroid microsomal antibodies (titre 6400) and a normal antithyroglobulin antibody level. These results were consistent with hypothyroidism due to Hashimoto's thyroiditis. She was commenced on L-thyroxine 100 µg daily. She has remained on interferon β -1b therapy, and her thyroid function has been adequate on replacement

278

documented the occurrence of autoimmune hyperthyroidism or hypothyroidism¹⁻³ and increased autoantibody levels^{2,3} in association with this treatment for MS. Another type 1 interferon, interferon α , which is widely used to treat chronic viral hepatitis, has been reported to induce autoimmune disease, including hypothyroidism.⁴

Autoimmune thyroid disease, as well as other autoimmune diseases, can occur in MS patients not receiving interferon ß therapy,⁵ but it is unclear whether the occurrence of these diseases is increased in MS patients. Some studies have found an increased occurrence of autoimmune diseases but others have not. It is established that patients with MS have an increased frequency of elevated autoantibodies, including antithyroid antibodies,6 indicating that patients with MS are predisposed to autoimmunity in general. Thus it is possible that interferon ß-1b unmasks or triggers autoimmune diseases on the background of such a predisposition. It would be anticipated that interferon ß-1a would have a similar effect. Interestingly, the presence of antithyroid antibodies prior to treatment with interferon α predisposes patients with chronic viral hepatitis to the development of autoimmune hypothyroidism during treatment.7 Durelli and colleagues3 found that all three patients with persistent autoimmune thyroid dysfunction arising during interferon ß-1b therapy for MS had a family history of thyroid disease or had elevated antithyroid antibodies prior to therapy. Recently it has been shown that interferon α and interferon β inhibit B cell receptor-mediated apoptosis,8 which may account for the increased autoantibodies and autoimmune disease in patients treated with these interferons.

Physicians should be alerted to the possibility of altered thyroid function in MS patients receiving interferon β -1b and should perform thyroid function tests in patients with suggestive symptoms. In view of the beneficial effect of interferon β -1b in MS, we decided to continue our patients on interferon β -1b therapy while treating the hypothyroidism with L-thyroxine.

provided by University of Queensland eSpace	
piondut to you by T CORE	View metadata, citation and similar papers at <u>core.ac.uk</u>
interferon is-1b therapy for MS. Recent reports have	Royal Brisbane Hospital,

Aust NZ J Med 2000; 30

LETTERS AND CASE REPORTS

M. P. PENDER, Professor of Medicine, Department of Medicine, The University of Queensland, and Director of Neurology, Royal Brisbane Hospital, Brisbane, Qld.

Date of submission: 27 October 1999

References

- 1. Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol 1997; 57: 1169-70.
- Rotondi M, Oliviero A, Profice P et al. Occurrence of thyroid autoimmunity and dysfunction throughout a ninemonth follow-up in patients undergoing interferon-β therapy for multiple sclerosis. J Endocrinol Invest 1998; 21: 748-52.

- Durelli L, Ferrero B, Oggero A et al. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 1999; 162: 74-83.
- 4. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994; 10: 115-50.
- 5. Pender MP. Multiple sclerosis. In: Pender MP, McCombe PA (Eds). Autoimmune neurological disease. Cambridge: Cambridge University Press, 1995; 89-154.
- Spadaro M, Amendolea MA, Mazzucconi MG et al. Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Multiple Sclerosis 1999; 5: 121-5.
- 7. Deutsch M, Dourakis S, Manesis EK et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26: 206-10.
- 8. Su L, David M. Inhibition of B cell receptor-mediated apoptosis by IFN. J Immunol 1999; 162: 6317-21.

DEPARTMENT of HEALTH and HUMAN SERVICES



Interventional Cardiologist

The Launceston General Hospital requires a Cardiologist to provide the following in services:

• Coronary angiography and emergency angioplasty and stenting.

- · Clinical support for the Coronary Care Unit and Inpatient cardiology.
- Pacemaker insertion and follow up.
- · Support for non-invasive cardiology.

In addition, opportunities exist for undergraduate, and postgraduate teaching and research.

The Launceston General Hospital is a teaching hospital for the University of Tasmania Medical School for Fifth and Sixth year students. Support for research is available from the Clifford Craig Research Trust upon application.

Enquiries to:

Associate Professor Rob Fassett Director of Medicine, Launceston General Hospital Phone: 03 63487190 E-mail: rob.fassett@dchs.tas.gov.au

Applications to:

The Recruitment Unit Human Resource Operations GPO Box 125B Hobart Tasmania 7001 Or by e-mail to dhhs.recruitment@dchs.tas.gov.au

More information on the department is available at our website: http://www.dchs.tas.gov.au

The Department of Health & Human Services is an Equal Opportunity Employer and provides a Smokefree Workplace

LETTERS AND CASE REPORTS

Aust NZ J Med 2000; 30